New indication approved in EU for Celgene's Revlimid

15 July 2016

US biotech firm Celgene (Nasdaq: CELG) says it has obtained approval from the European Commission for the use of Revlimid (lenalidomide) for patients with relapsed/refractory mantle cell lymphoma (MCL).

MCL is a rare sub-type of aggressive non-Hodgkin’s lymphoma (NHL) with one of the poorest prognoses among all lymphomas. This novel indication for Revlimid offers a new opportunity to MCL patients across the European Union and confirms Celgene’s position in the front line to address the highly unmet medical needs of lymphoma patients, the company said.

Already indicated for the treatment of patients with multiple myeloma and myelodysplastic syndromes, Revlimid shows its potential to treat other types of cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK